Literature DB >> 14648782

Conformal chemoradiation for primary and metastatic liver malignancies.

Laura A Dawson1, Cornelius J McGinn, Theodore S Lawrence.   

Abstract

Historically, radiation therapy has played a minor role in the management of patients with unresectable primary hepatobiliary malignancies and liver metastases from colorectal cancer. This can be attributed chiefly to the low tolerance of the whole liver to radiation. Three-dimensional radiation planning techniques have allowed much higher doses of radiation to be delivered to focal liver tumors, while sparing the majority of the normal liver. When combined with fluorodeoxyuridine (FUdR), high-dose focal liver radiation is associated with excellent response rates, local control, and survival in patients with large unresectable tumors. There appears to be a radiation dose response for intrahepatic malignancies. Advancements in tumor imaging, radiation techniques that can safely deliver higher doses of radiation, novel tumor radiation sensitizers, and normal-tissue radioprotectors should substantially improve the outcome of patients with unresectable intrahepatic malignancies treated with chemoradiation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 14648782     DOI: 10.1002/ssu.10043

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  9 in total

1.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

Review 2.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

Review 3.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

4.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

5.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

6.  CT- versus coregistered FDG-PET/CT-based radiation therapy plans for conformal radiotherapy in colorectal liver metastases: a dosimetric comparison.

Authors:  Cem Parlak; Erkan Topkan; Serhat Sonmez; Cem Onal; Mehmet Reyhan
Journal:  Jpn J Radiol       Date:  2012-06-30       Impact factor: 2.374

7.  Radioembolization for hepatocellular carcinoma using TheraSphere®.

Authors:  Safiyya Mohamed Ali
Journal:  Saudi J Gastroenterol       Date:  2011 May-Jun       Impact factor: 2.485

Review 8.  Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma.

Authors:  Khalid A Jazieh; Mohammad Arabi; Azzam A Khankan
Journal:  Saudi J Gastroenterol       Date:  2014 Nov-Dec       Impact factor: 2.485

9.  Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization.

Authors:  Mohamed E Salem; Nitin Jain; Gregory Dyson; Stephanie Taylor; Sherif M El-Refai; Minsig Choi; Anthony F Shields; Jeffery Critchfield; Philip A Philip
Journal:  ISRN Oncol       Date:  2013-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.